news
UK approval for Pompe Disease therapy
16 August 2023 | By
The MHRA has granted marketing authorisation for a two-component therapy for adults with late-onset Pompe Disease, a rare disorder.
List view / Grid view
National Institue for Health and Care Excellence (NICE)
news
NICE recommends combo therapy for gastroesophageal cancer
Nivolumab together with chemotherapy has been recommended in NICE final draft guidance for treatment of gastroesophageal cancer.
news
Fund to fast-track innovative drugs to NHS
The UK Government has announced the launch of the Innovative Medicines Fund to bring cutting-edge treatment more quickly to NHS patients.
news
NICE rules nivolumab is not cost effective for use on NHS
The regulatory body said that due to uncertainties surrounding the long-term effectiveness of nivolumab (Opdivo), its cost-effectiveness estimates are too high.
news
NICE recommends fremanezumab for chronic migraine prevention
The UK’s National Institute for Health and Care Excellence, NICE, recommends the use of fremanezumab on the NHS for preventing chronic migraine.
news
NICE fails to recommend the combination of pembrolizumab and axitinib for kidney cancer on NHS
The National Institute for Health and Care Excellence (NICE) has stated that combined use of the drugs pembrolizumab and axitinib is not recommended for untreated advanced renal cell carcinoma in adults.
